Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer

CompletedOBSERVATIONAL
Enrollment

763

Participants

Timeline

Start Date

May 14, 2021

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2022

Conditions
Metastatic Breast Cancer
Interventions
OTHER

None (Observational study)

The data on different types of treatment received by the patients, socio-demographics, and clinico-pathological characteristics and healthcare resource utilisation will be extracted from patients' medical records (both alive and deceased).

Trial Locations (44)

100

Research Site, Taipei

404

Research Site, Taichung

824

Research Site, Kaohsiung City

2065

Research Site, St Leonards

2109

Research Site, Macquarie

2145

Research Site, Parramatta

2305

Research Site, Newcastle

2841

Research Site, Seoul

5505

Research Site, Seoul

6351

Research Site, Seoul

8308

Research Site, Seoul

10408

Research Site, Goyang

11217

Research Site, Taipei

11490

Research Site, Taipei

21565

Research Site, Incheon

40705

Research Site, Taichung

70403

Research Site, Tainan City

71004

Research Site, Tainan County

119228

Research Site, Singapore

150001

Research Site, Hong Kong

217562

Research Site, Singapore

308433

Research Site, Singapore

609606

Research Site, Singapore

Unknown

Research Site, Perth

Research Site, Hong Kong

Research Site, Kowloon

69056 037

Research Site, Manaus

60336 232

Research Site, Fortaleza

29308 014

Research Site, Cachoeiro de Itapemirim

40170 110

Research Site, Salvador

41950 640

Research Site, Salvador

80040 170

Research Site, Curitiba

85020 450

Research Site, Caxias do Sul

90035 001

Research Site, Porto Alegre

90610 000

Research Site, Porto Alegre

88301 220

Research Site, Itajaí

09060 650

Research Site, Santo André

60416 130

Research Site, Fortaleza

74605 070

Research Site, Goiânia

22250 905

Research Site, Rio de Janeiro

01321 001

Research Site, São Paulo

04502 001

Research Site, São Paulo

03080

Research Site, Seoul

03722

Research Site, Seoul

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY